GLP1R and metabolic syndrome: The goal of this newly developed drug would be to hypothetically maximize weight loss results and achieve better control of metabolic syndrome, while simultaneously limiting the potential adverse gynecological events and tumorigenesis potential of estrogen, by ensuring targeted estrogen delivery specifically to GLP-1 receptor expressing cells [87].